HaTay Pharmaceutical JSC

HaTay Pharmaceutical JSC Equity

The The Equity of HaTay Pharmaceutical JSC (DHT.VN) as of Nov 2, 2026 is 1.03 T VND. In the previous year, The Equity was 1.04 T VND — a change of -0.84% (lower).

Equity

1.03 TVND

YoY

-0.84%

Last updated:

In 2024, HaTay Pharmaceutical JSC's equity was 1.03 T VND, a -0.84% increase from the 1.04 T VND equity in the previous year.

The HaTay Pharmaceutical JSC Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
227.98 B VND
Jan 1, 2018
249.85 B VND
Jan 1, 2019
288.73 B VND
Jan 1, 2020
326.23 B VND
Jan 1, 2021
729.77 B VND
Jan 1, 2022
773.34 B VND
Jan 1, 2023
1.04 T VND
Jan 1, 2024
1.03 T VND
The HaTay Pharmaceutical JSC Equity history
YEAREquityYoY
1.03 TVND-0.84%
1.04 TVND+34.26%
773.34 BVND+5.97%
729.77 BVND+123.70%
326.23 BVND+12.99%
288.73 BVND+15.56%
249.85 BVND+9.59%
227.98 BVND+29.32%
176.29 BVND+22.63%
143.76 BVND+9.50%
131.30 BVND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

HaTay Pharmaceutical JSC Stock analysis

What does HaTay Pharmaceutical JSC do? Ha Tay Pharmaceutical JSC generates revenue through the manufacturing, import, and export of pharmaceuticals, cosmetics, and medical equipment. The company sells its products via wholesale and retail channels, targeting healthcare providers, pharmacies, and consumers. It also engages in the production and trading of cosmetic products, supplemental food, and laboratory chemicals, alongside medical equipment and supplies. The firm completed the acquisition of a 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company in 2013, expanding its market presence in pharmaceuticals and medical equipment. The company operates in the pharmaceutical sector, serving healthcare institutions, retail pharmacies, and end consumers. Its revenue streams include the sale of drugs, cosmetics, medical equipment, and related supplies. Additional income comes from supermarket operations, real estate leasing, and vocational training services, though these are secondary to its core pharmaceutical business. Ha Tay Pharmaceutical JSC's primary customers are healthcare providers, pharmacies, and consumers purchasing pharmaceuticals, cosmetics, and medical equipment. The firm's product portfolio spans drugs, vaccines, cosmetic products, supplemental food, and laboratory chemicals, with a focus on manufacturing and trading. The acquisition of the 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company has strengthened its position in the medical equipment market. HaTay Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Equity Details

Analyzing HaTay Pharmaceutical JSC's Equity

HaTay Pharmaceutical JSC's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding HaTay Pharmaceutical JSC's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating HaTay Pharmaceutical JSC's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

HaTay Pharmaceutical JSC's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in HaTay Pharmaceutical JSC’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about HaTay Pharmaceutical JSC stock

The Equity of HaTay Pharmaceutical JSC is 1.03 T VND in 2024.

The Equity of HaTay Pharmaceutical JSC changed from 1.04 T VND to 1.03 T VND, representing a -0.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity HaTay Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

The Equity's VND is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's HaTay Pharmaceutical JSC historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — HaTay Pharmaceutical JSC

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — HaTay Pharmaceutical JSC